Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …

Methods From 1 January to 31 December 2012, 98,213 AF patients were selected from the
NHIRD database. A Markov model was constructed that combined published secondary …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …

Background and objective To evaluate the cost-effectiveness of new anticoagulants and
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Background Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …